Updated:
Focalpoint Ventures
Empath Ventures is a venture capital firm that invests in the psychedelics industry. Focalpoint Ventures has made 8 investments. Their latest investment was in...
Overview
Empath Ventures is a venture capital firm that invests in the psychedelics industry. Focalpoint Ventures has made 8 investments. Their latest investment was in Xylo Bio as part of their Seed VC - III on May 31, 2024.
General information
Firm type
Venture Capital
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Sector focus
Frequently asked questions
What is Focalpoint Ventures' investment thesis?
The firm invests under the XEIA Venture Partners brand with a thesis it calls 'Human 3,' targeting the convergence of life sciences, AI, hardware, and deep tech to advance human health, wellbeing, and performance. Its portfolio companies combine these disciplines in ways that often defy traditional categorization.
What investment stages does Focalpoint Ventures target?
XEIA Venture Partners focuses on early-stage startups. The firm has not publicly specified a preferred check size or series range, but its positioning points to seed and early-venture rounds for companies still forming their core scientific and product foundations.
Which sectors does Focalpoint Ventures explicitly avoid?
The firm is explicitly concentrated on health, wellbeing, and performance — it does not invest in general SaaS, enterprise software, fintech, or consumer internet plays that fall outside the intersection of human biology and technology. Its narrow 'Human 3' mandate implicitly excludes sectors where the upgrade of the human body or mind is not the central value proposition.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: